Christian Fernandez Olortegui

Amazing video beautifully demonstrating #radiationoncology by @TargetingCancer shared at @roecsg 2019 symposium #roecsg #radonc #target youtu.be/4mkj-mYwSl0

🚨The sequel is here!! The other 👞 drops. Cribriform morphology in ProtecT — now in prostatectomy specimens #ProstateCancer #radonc #UroSoMe @UroToday @APCCC_Lugano @PCF_Science @OncoAlert 🧵1️⃣

Footage of ICE kidnapping PRE-K TEACHERS in Chicago that my sister sent to me. Rayito de Sol on Addison

Financial Principles for Radiation Oncologists Bootcamp Part 1: How to Plan Your Financial Future With @A_CT_SimMDJD Collaboration w @RadiumSociety @ASTRO_org @ACRORadOnc @ARRO_org @TrudyWuMD @MaryMahoney02 #radonc Parts 2-3 coming soon youtube.com/watch?v=8cjV3D…

SBRT vs. Ablation for Kidney Cancer: A Game-Changer? @OncoAlert 🚀🔥 #RadOnc 🧵 Ablative therapies for localized renal cell carcinoma (RCC): What’s the best approach? 📢 A new Lancet Oncology study compares SBRT, radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation. How do these stack up? Let’s break it down. 👇 #app-1" target="_blank" rel="nofollow noopener">thelancet.com/journals/lanon…

🚨 The 2024 FROGG Guidelines for Post-Prostatectomy Radiation Therapy (PPRT) are here, bringing groundbreaking updates backed the by the latest evidence❗️@OncoAlert 🧵1/7

Do all early-stage breast cancer patients need axillary surgery? The INSEMA trial challenges this long-standing practice, showing that skipping sentinel lymph node biopsy (SLNB) may be safe for select patients. ☢️ plays a key role. Let’s dive into the data. 🧵 1/13#RadOnc #BreastSurgery”

RACE-GB is out! Congrats to authors for FIRST RCT of RT in gallbladder cancer. N=135 w unresectable GBC, after 4c chemo, addition of RT (vs. obs) improved OS from 4 to 10 months. Several limitations (single center, chemo gem/cis & 4 mo) but OS benefit shouldn’t be ignored.

Just in 👉 @JCO_ASCO Benefit of Whole-Pelvis Radiation ☢️ for Patients With #MIBC ascopubs.org/doi/10.1200/JC… 👇👇👇TWEETORIAL 👇👇👇

Consensus guidelines on the diagnosis and management of RT pneumonitis ▶️ Delphi consensus ▶️Practical guide to assess risk in individual patients ▶️unmet need-> clarify the relationship between RT-drug-induced pneumonitis + optimal management strategies sciencedirect.com/science/articl…

Really incredible article about an insurance company disciplining a doctor for following the standard of care. journals.lww.com/em-news/fullte… Looks like their “experts” are just as bad as some of the most crooked plaintiff experts I see.

Thrilled to see that KEYNOTE-0412 has been published in Lancet Oncology. TL/DR: The utility of an CRT/IO combination hasn’t been figured out yet, but the field is getting much closer. thelancet.com/action/showPdf…

MONTHs ago, I saw a young patient who lost all her hair one day. And as someone who developed alopecia areata ophiasis and lost all her eyebrows and hairlines, I KNOW I needed to act fast. So far, this is the despicable game we have been asked to play with coordinated care: - I tried “traditional” therapies with steroids, injections, etc. Failed (of course). - I prescribed a Biologics that’s FDA approved for alopecia areata for patients over 12, and documented (heartbreaking) photos, and detailed reasoning why we needed the medication - Insurance denied it. (#1) - I appealed, got denial #2. - I requested peer to peer discussion and blocked my busy clinic time to do it. - A non-physician called my nursing staff and REFUSED to talk to me and denied my demand to talk to a peer, so even my peer to peer was denied! (#3) - Told us we needed an exception application. I put together a 38 page letter including the FDA approval and clinical trials and my notes, again. - We didn’t hear back for weeks. - Then we got denial #4 because we “didn’t file the right appeal.” - I filed yet ANOTHER appeal. - We’ve not heard back again for weeks now. We keep calling and be put on hold for 30 minutes at a time. Here is what prior authorizations do: - they aim to drive cost down for insurance companies, and serves as few patients as possible - they waste clinicians’ time for patient care - they waste nursing staff’s time for patient care - they hurt patients by dictating what happens in the exam rooms without actually being there 👏Prior 👏 Authorizations 👏 Are 👏SCAMS 👏 and 👏 they 👏 harm 👏 patients 👏 You know what I’m going to do? I’m going to get my patient the FUCKING medicine. 🤬 zedzha.com/blog/hide-away…

@toddscarbrough Who is giving 26Gy boosts? 🤔

Evidence accumulates to give #radonc boost the boot in breast cancer whenever possible For cT1-2N0-2a age <50, (higher dose) boost increases local control by ~2% at 10 years, but also increases moderate/severe scarring by ~20% "'[LC] benefit does not justify the increased impact on cosmetic outcomes" event.eortc.org/ebcc14/2024/03… news-medical.net/news/20240321/… thegreenjournal.com/article/S0167-…

1/Can’t seem to strike the right CHORD when it comes to chordomas? Do chordomas frighten you to the core? What do you KNOW about the NOTOchord? Never fear, here’s a thread to teach you what you NEED to know about the diagnosis & treatment of chordomas!

First prospective data of SBRT for early stage NSCLC in pts with interstitial lung disease 👉 risk of treatment-related mortality 7.7% 👉 median OS 25mo 👍 prespecified acceptability thresholds for toxicity & efficacy met 👏 @drdavidpalma and colleagues jamanetwork.com/journals/jamao…

Results of this randomized clinical trial suggest that after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma, radiotherapy alone was noninferior to chemoradiotherapy in terms of 3-year progression-free survival. ja.ma/3SFqZBw

No cervical cancer cases have been detected in women who have been fully vaccinated against HPV, Public Health Scotland has revealed. i.stv.tv/48ZbmLB

🚨🚨🚨 Rectal Cancer Tweetorial!! Rectal cancer is a highly heterogeneous disease with rapid evolution in practice. Let's review current data to generate a pragmatic, patient-centric, approach to management! #GI24 #GIonc #RadOnc Thank you @ASCO for the opportunity!🙏🏽 1/

Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer @Annals_Oncology doi.org/10.1016/j.anno… 👉1st randomised trial addressing the timing of surgery after nCRT 🧐Do not delay surgery >6 weeks, TRG 4 fared particularly badly @myESMO

Targeted geneexpression biomarker for Meningioma risk stratification · Re-classified over 1/2meningiomas compared to conventional clinical criteria · Predict which Gr2 benefit from RT · rdcu.be/drt6i